Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

被引：16
|
作者：
Wang, Yang [1 ]
Li, Jingxin [2 ]
Wang, Yuxiao [1 ]
Gu, Wei [3 ]
Zhu, Fengcai [1 ,2 ]
机构：
[1] Southeast Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
[2] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期
关键词：
clinical trials; high-risk population; immunization strategy; pneumococcal polysaccharide vaccine; vaccine efficacy; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYOCARDIAL-INFARCTION; WORKING-AGE ADULTS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; MATERNAL IMMUNIZATION; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; CLINICAL EFFECTIVENESS; DISEASE EPIDEMIOLOGY;
D O I：
10.1080/21645515.2017.1409316
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people >= 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.
引用
收藏
页码：1003 / 1012
页数：10
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
    Choi, Min-Joo
    Kang, Shin-On
    Oh, Jin-Jeong
    Park, Seong-Beom
    Kim, Min-Ja
    Cheong, Hee-Jin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1914 - 1922
  • [42] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [43] Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
    Russell, F. M.
    Carapetis, J. R.
    Satzke, C.
    Tikoduadua, L.
    Waqatakirewa, L.
    Chandra, R.
    Seduadua, A.
    Oftadeh, S.
    Cheung, Y. B.
    Gilbert, G. L.
    Mulholland, E. K.
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (12) : 1970 - 1976
  • [44] Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly
    Won, Heehyun
    Kim, Jeong Ah
    Jeong, Na-Young
    Choi, Nam-Kyong
    VACCINE, 2024, 42 (13) : 3190 - 3196
  • [45] Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly
    Won, Heehyun
    Kim, Jeong Ah
    Jeong, Na-Young
    Choi, Nam-Kyong
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 24 - 25
  • [46] Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
    Falkenhorst, Gerhard
    Remschmidt, Cornelius
    Harder, Thomas
    Hummers-Pradier, Eva
    Wichmann, Ole
    Bogdan, Christian
    PLOS ONE, 2017, 12 (01):
  • [47] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
    Shiramoto, Masanari
    Hanada, Ryuzo
    Juergens, Christine
    Shoji, Yasuko
    Yoshida, Mizuki
    Ballan, Barry
    Cooper, David
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2198 - 2206
  • [48] Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: A Belgian consensus report
    Peetermans, WE
    Van de Vyver, N
    Van Laethem, Y
    Van Damme, P
    Thiry, N
    Trefois, P
    Geerts, P
    Schetgen, M
    Peleman, R
    Swennen, B
    Verhaegen, J
    ACTA CLINICA BELGICA, 2005, 60 (06) : 329 - 337
  • [49] Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects
    Ciprero, Karen
    Zykov, Kirill A.
    Briko, Nikolay I.
    Shekar, Tulin
    Sterling, Tina M.
    Bitieva, Elizaveta
    Stek, Jon E.
    Musey, Luwy
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (08) : 2142 - 2147
  • [50] Analysis of Vaccination Rates of 23-Valent Pneumococcal Polysaccharide Vaccine in Hospitalized Patients with Diabetes
    Seagroves, Amy
    Reh, Christina S.
    Bischoff, Nathaniel
    Nally, Laura M.
    Singh, Jasjit
    DIABETES, 2017, 66 : A377 - A378
12345